The present invention relates to nutritional supplements for the human diet used to manipulate HDL cholesterol, LDL cholesterol, and triglyceride levels in human blood plasma. The invention contains a novel combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present in Fish Oil, alpha-linolenic acid (ALA) present in Flaxseed Oil, Vitamin E in the form of d-alpha-tocopherol, Allicin present in Garlic, Phosphatidylcholine present in Lecithin, plant phytochemicals present in Parsley herb, citrus flavonoids present in Lemon fruit and Rutin (from Sophora japonica), and Capsaicin present in Cayenne Pepper.

The invention discloses a composition exhibiting enhanced bioavailability comprising tri-molecular complex of a natural compound or a natural compound containing component, a divalent or tri-valent metal ion and a phospholipid embedded in natural matrix. The composition of the invention further exhibits a sustained release profile for the natural compound or natural compound containing component. The invention further discloses a process for manufacturing the tri-molecular complex containing composition.

The invention discloses a composition exhibiting enhanced bioavailability comprising tri-molecular complex of a natural compound or a natural compound containing component, a divalent or tri-valent metal ion and a phospholipid embedded in natural matrix. The composition of the invention further exhibits a sustained release profile for the natural compound or natural compound containing component. The invention further discloses a process for manufacturing the tri-molecular complex containing composition.

Calcium hydroxide nanoparticles (Ca(OH).sub.2NPs) synthesized using carob pulp extract may be hexagonal nanoparticles with a diameter ranging from about 31.22 nm to about 81.22 nm. The Ca(OH).sub.2NPs may be synthesized by heating ethylene glycol, adding calcium hydroxide to the ethylene glycol to provide a first mixture, heating the first mixture, adding a carob pulp aqueous extract to the first mixture to form a second mixture, heating the second mixture, adding sodium hydroxide (NaOH) to the second mixture to form a third mixture, heating the third mixture, resting the third mixture at room temperature after heating, centrifuging the third mixture, collecting a colloid sediment, extracting any unwanted contaminants from the colloid sediment, and drying the colloid sediment to obtain Ca(OH).sub.2NPs.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention relates in particular to a cosmetic composition comprising, in a physiologically acceptable medium, at least: a) a cosmetic agent consisting of galactomannans with molar masses comprised between 5 and 630 kDa, preferably between 5 and 120 kDa, more preferably between 8 and 80 kDa, and cross-linked sulfated galactans with molar masses comprised between 7 and 3000 kDa, preferably between 7 and 1100 kDa, more preferably between 8 and 200 kDa, and b) a Theobroma cacao L bean hydrolysate, and its use in particular for maintaining the balance of the skin microbiota and promoting and/or improving the wear of make-up.

The present invention relates in particular to a cosmetic composition comprising, in a physiologically acceptable medium, at least: a) a cosmetic agent consisting of galactomannans with molar masses comprised between 5 and 630 kDa, preferably between 5 and 120 kDa, more preferably between 8 and 80 kDa, and cross-linked sulfated galactans with molar masses comprised between 7 and 3000 kDa, preferably between 7 and 1100 kDa, more preferably between 8 and 200 kDa, and b) a Theobroma cacao L bean hydrolysate, and its use in particular for maintaining the balance of the skin microbiota and promoting and/or improving the wear of make-up.

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.